PURPOSE: Development of new hepaticoenteric anastomotic vessels may occur after endovascular skeletonization of the hepatic artery. Left untreated, they can serve as pathways for nontarget radioembolization. The authors reviewed the incidence, anatomy, management, and significance of collateral vessel formation in patients undergoing radioembolization. MATERIALS AND METHODS: One hundred thirty-eight treatments performed on 122 patients were reviewed. Each patient underwent a preparatory digital subtraction angiogram (DSA) and embolization of all hepaticoenteric vessels in preparation for yttrium-90 ((90)Y) administration. Successful skeletonization was verified by C-arm computed tomography (CACT) and technetium-99m macroaggregated albumin ((99m)TcMAA) scintigraphy. During the subsequent treatment session, DSA and CACT were repeated before administration of (90)Y, and the detection of extrahepatic perfusion prompted additional embolization. RESULTS: Forty-two patients (34.4%) undergoing 43 treatments (31.2%) required adjunctive embolization of hepaticoenteric vessels immediately before (90)Y administration. Previous scintigraphy findings showed extrahepatic perfusion in only three cases (7.1%). Vessels were identified by DSA in 54.1%, by CACT in 4.9%, or required both in 41.0%. The time interval between angiograms did not correlate with risk of requiring reembolization (P = .297). A total of 19.7% of vessels were new collateral vessels not visible during the initial angiography. Despite reembolization, three patients (7.1%) had gastric or duodenal ulceration, compared with 1.3% who never had visible collateral vessels, all of whom underwent whole-liver treatment with resin microspheres (P = .038). CONCLUSIONS: Development of collateral hepaticoenteric anastomoses occurs after endovascular skeletonization of the hepatic artery. Identified vessels may be managed by adjunctive embolization, but patients appear to remain at increased risk for gastrointestinal complications. Copyright 2010 SIR. Published by Elsevier Inc. All rights reserved.
PURPOSE: Development of new hepaticoenteric anastomotic vessels may occur after endovascular skeletonization of the hepatic artery. Left untreated, they can serve as pathways for nontarget radioembolization. The authors reviewed the incidence, anatomy, management, and significance of collateral vessel formation in patients undergoing radioembolization. MATERIALS AND METHODS: One hundred thirty-eight treatments performed on 122 patients were reviewed. Each patient underwent a preparatory digital subtraction angiogram (DSA) and embolization of all hepaticoenteric vessels in preparation for yttrium-90 ((90)Y) administration. Successful skeletonization was verified by C-arm computed tomography (CACT) and technetium-99m macroaggregated albumin ((99m)TcMAA) scintigraphy. During the subsequent treatment session, DSA and CACT were repeated before administration of (90)Y, and the detection of extrahepatic perfusion prompted additional embolization. RESULTS: Forty-two patients (34.4%) undergoing 43 treatments (31.2%) required adjunctive embolization of hepaticoenteric vessels immediately before (90)Y administration. Previous scintigraphy findings showed extrahepatic perfusion in only three cases (7.1%). Vessels were identified by DSA in 54.1%, by CACT in 4.9%, or required both in 41.0%. The time interval between angiograms did not correlate with risk of requiring reembolization (P = .297). A total of 19.7% of vessels were new collateral vessels not visible during the initial angiography. Despite reembolization, three patients (7.1%) had gastric or duodenal ulceration, compared with 1.3% who never had visible collateral vessels, all of whom underwent whole-liver treatment with resin microspheres (P = .038). CONCLUSIONS: Development of collateral hepaticoenteric anastomoses occurs after endovascular skeletonization of the hepatic artery. Identified vessels may be managed by adjunctive embolization, but patients appear to remain at increased risk for gastrointestinal complications. Copyright 2010 SIR. Published by Elsevier Inc. All rights reserved.
Authors: Jan Best; Clemens Schotten; Jens M Theysohn; Axel Wetter; Stefan Müller; Sonia Radünz; Maren Schulze; Ali Canbay; Alexander Dechêne; Guido Gerken Journal: Ann Gastroenterol Date: 2016-09-30
Authors: Arthur J A T Braat; Jip F Prince; Rob van Rooij; Rutger C G Bruijnen; Maurice A A J van den Bosch; Marnix G E H Lam Journal: Eur Radiol Date: 2017-08-07 Impact factor: 5.315
Authors: Piotr Piasecki; Krzysztof Brzozowski; Piotr Ziecina; Marek Wierzbicki; Anna Budzynska; Andrzej Mazurek; Miroslaw Dziuk; Maciej Maciak; Edward Iller; Jerzy Narloch Journal: J Clin Med Date: 2019-09-24 Impact factor: 4.241
Authors: Lindsay B Young; Marcin Kolber; Michael J King; Mona Ranade; Vivian L Bishay; Rahul S Patel; Francis S Nowakowski; Aaron M Fischman; Robert A Lookstein; Edward Kim Journal: J Interv Med Date: 2022-05-21
Authors: Alicia S Borggreve; Anadeijda J E M C Landman; Coco M J Vissers; Charlotte D De Jong; Marnix G E H Lam; Evelyn M Monninkhof; Jip F Prince Journal: Cardiovasc Intervent Radiol Date: 2016-03-02 Impact factor: 2.740